CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655 ...
NVL-655 is a novel, brain-penetrant, ALK-selective tyrosine kinase inhibitor (TKI) developed to address emergent treatment resistance and brain metastases while minimizing off-target central nervous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback